Research snapshot · Not reviewed

NTRANatera

Genetic testing, MRD, oncology biomarkers

Open NTRA in Robinhood ↗

WATCH

Conviction●○○○○1 of 5

Research target—Snapshot target

Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed

Market cap$40.00BSnapshot value

The thesis

Genetic testing + MRD pure-play. Signatera (MRD) and Panorama (NIPT) drive recurring test-volume revenue. High growth but negative earnings.

Catalysts

Signatera MRD clinical adoption accelerating; oncology guideline inclusion; women's health franchise stability (Panorama).

What breaks it

Negative earnings (~$1.62 EPS loss); reimbursement concentration risk; competitive pressure from Guardant (Reveal) and Exact Sciences; high valuation multiple.

Social sentiment

needs X/Reddit sentiment sweep

Snapshot · Not reviewed

Smart money

🟢 Lean-Bull · ins-$12.8M · 13F 13+/11- · short↓0.17

Snapshot · Not reviewed